ATRA Quote, Financials, Valuation and Earnings

ACADIA Pharmaceuticals, Inc. has a net margin of -124.62% compared to Atara Biotherapeutics, Inc.'s net margin of 25.76%. Atara Biotherapeutics, Inc.'s return on equity of -2818.48% beat ACADIA Pharmaceuticals, Inc.'s return on equity of 34.23%.

Atara Biotherapeutics, Inc. has a consensus price target of $8.67, signalling upside risk potential of 94.76%. On the other hand ACADIA Pharmaceuticals, Inc. has an analysts' consensus of $31.21 which suggests that it could grow by 41.67%. Given that Atara Biotherapeutics, Inc. has higher upside potential than ACADIA Pharmaceuticals, Inc., analysts believe Atara Biotherapeutics, Inc. is more attractive than ACADIA Pharmaceuticals, Inc..

Atara Biotherapeutics, Inc. has a beta of -0.433, which suggesting that the stock is 143.296% less volatile than S&P 500. In comparison ACADIA Pharmaceuticals, Inc. has a beta of 0.660, suggesting its less volatile than the S&P 500 by 33.951%.

Atara Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ACADIA Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Atara Biotherapeutics, Inc. pays -- of its earnings as a dividend. ACADIA Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Atara Biotherapeutics, Inc. quarterly revenues are $3.5M, which are smaller than ACADIA Pharmaceuticals, Inc. quarterly revenues of $278.6M. Atara Biotherapeutics, Inc.'s net income of -$4.3M is lower than ACADIA Pharmaceuticals, Inc.'s net income of $71.8M. Notably, Atara Biotherapeutics, Inc.'s price-to-earnings ratio is 2.03x while ACADIA Pharmaceuticals, Inc.'s PE ratio is 14.17x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Atara Biotherapeutics, Inc. is 0.35x versus 3.54x for ACADIA Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Alnylam Pharmaceuticals, Inc. has a net margin of -124.62% compared to Atara Biotherapeutics, Inc.'s net margin of 16.99%. Atara Biotherapeutics, Inc.'s return on equity of -2818.48% beat Alnylam Pharmaceuticals, Inc.'s return on equity of 107.73%.

Atara Biotherapeutics, Inc. has a consensus price target of $8.67, signalling upside risk potential of 94.76%. On the other hand Alnylam Pharmaceuticals, Inc. has an analysts' consensus of $467.62 which suggests that it could grow by 48.74%. Given that Atara Biotherapeutics, Inc. has higher upside potential than Alnylam Pharmaceuticals, Inc., analysts believe Atara Biotherapeutics, Inc. is more attractive than Alnylam Pharmaceuticals, Inc..

Atara Biotherapeutics, Inc. has a beta of -0.433, which suggesting that the stock is 143.296% less volatile than S&P 500. In comparison Alnylam Pharmaceuticals, Inc. has a beta of 0.350, suggesting its less volatile than the S&P 500 by 65.025%.

Atara Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Atara Biotherapeutics, Inc. pays -- of its earnings as a dividend. Alnylam Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Atara Biotherapeutics, Inc. quarterly revenues are $3.5M, which are smaller than Alnylam Pharmaceuticals, Inc. quarterly revenues of $1.1B. Atara Biotherapeutics, Inc.'s net income of -$4.3M is lower than Alnylam Pharmaceuticals, Inc.'s net income of $186.4M. Notably, Atara Biotherapeutics, Inc.'s price-to-earnings ratio is 2.03x while Alnylam Pharmaceuticals, Inc.'s PE ratio is 139.29x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Atara Biotherapeutics, Inc. is 0.35x versus 11.30x for Alnylam Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer Inc. has a net margin of -124.62% compared to Atara Biotherapeutics, Inc.'s net margin of -9.34%. Atara Biotherapeutics, Inc.'s return on equity of -2818.48% beat Pfizer Inc.'s return on equity of 10.84%.

Atara Biotherapeutics, Inc. has a consensus price target of $8.67, signalling upside risk potential of 94.76%. On the other hand Pfizer Inc. has an analysts' consensus of $28.63 which suggests that it could grow by 3.8%. Given that Atara Biotherapeutics, Inc. has higher upside potential than Pfizer Inc., analysts believe Atara Biotherapeutics, Inc. is more attractive than Pfizer Inc..

Atara Biotherapeutics, Inc. has a beta of -0.433, which suggesting that the stock is 143.296% less volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.472, suggesting its less volatile than the S&P 500 by 52.751%.

Atara Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.24% to investors and pays a quarterly dividend of $0.43 per share. Atara Biotherapeutics, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 126.47% of its earnings as a dividend.

Atara Biotherapeutics, Inc. quarterly revenues are $3.5M, which are smaller than Pfizer Inc. quarterly revenues of $17.6B. Atara Biotherapeutics, Inc.'s net income of -$4.3M is higher than Pfizer Inc.'s net income of -$1.6B. Notably, Atara Biotherapeutics, Inc.'s price-to-earnings ratio is 2.03x while Pfizer Inc.'s PE ratio is 20.35x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Atara Biotherapeutics, Inc. is 0.35x versus 2.51x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals, Inc. has a net margin of -124.62% compared to Atara Biotherapeutics, Inc.'s net margin of 37.34%. Atara Biotherapeutics, Inc.'s return on equity of -2818.48% beat Vertex Pharmaceuticals, Inc.'s return on equity of 22.97%.

Atara Biotherapeutics, Inc. has a consensus price target of $8.67, signalling upside risk potential of 94.76%. On the other hand Vertex Pharmaceuticals, Inc. has an analysts' consensus of $517.08 which suggests that it could grow by 5.21%. Given that Atara Biotherapeutics, Inc. has higher upside potential than Vertex Pharmaceuticals, Inc., analysts believe Atara Biotherapeutics, Inc. is more attractive than Vertex Pharmaceuticals, Inc..

Atara Biotherapeutics, Inc. has a beta of -0.433, which suggesting that the stock is 143.296% less volatile than S&P 500. In comparison Vertex Pharmaceuticals, Inc. has a beta of 0.303, suggesting its less volatile than the S&P 500 by 69.725%.

Atara Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Atara Biotherapeutics, Inc. pays -- of its earnings as a dividend. Vertex Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Atara Biotherapeutics, Inc. quarterly revenues are $3.5M, which are smaller than Vertex Pharmaceuticals, Inc. quarterly revenues of $3.2B. Atara Biotherapeutics, Inc.'s net income of -$4.3M is lower than Vertex Pharmaceuticals, Inc.'s net income of $1.2B. Notably, Atara Biotherapeutics, Inc.'s price-to-earnings ratio is 2.03x while Vertex Pharmaceuticals, Inc.'s PE ratio is 32.05x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Atara Biotherapeutics, Inc. is 0.35x versus 10.53x for Vertex Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.